Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion: a Randomized Phase II Biomarker Trial in Subjects at Increased Risk

NCT06033092 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT06033092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06033092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion: a Randomized Phase II Biomarker Trial in Subjects at Increased Risk
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2024
Completion date
July 31, 2026
Enrollment
110 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

atm gene mutation, brca mutation, cdh1 gene mutation, chek2 gene mutation, ductal carcinoma in situ, lobular carcinoma in situ, palb2 gene mutation, rad51c gene mutation, rad51d gene mutation